Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q8WZA1
UPID:
PMGT1_HUMAN
Alternative names:
UDP-GlcNAc:alpha-D-mannoside beta-1,2-N-acetylglucosaminyltransferase I.2
Alternative UPACC:
Q8WZA1; D3DQ16; Q5VST2; Q5VST3; Q9BV55; Q9H9L8; Q9NXF9; Q9NYF7
Background:
Protein O-linked-mannose beta-1,2-N-acetylglucosaminyltransferase 1, also known as UDP-GlcNAc:alpha-D-mannoside beta-1,2-N-acetylglucosaminyltransferase I.2, plays a crucial role in O-mannosyl glycosylation. It catalyzes the addition of N-acetylglucosamine to O-linked mannose on glycoproteins, essential for the synthesis of the GlcNAc(beta1-2)Man(alpha1-)O-Ser/Thr moiety on alpha-dystroglycan and other proteins.
Therapeutic significance:
This protein's malfunction is linked to several diseases, including muscular dystrophy-dystroglycanopathy with brain and eye anomalies, intellectual disability, and retinitis pigmentosa. Understanding its role could lead to breakthroughs in treating these conditions.